Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Non-Customized |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Ezetimibe is a white crystalline powder, easily soluble in ethanol, methanol and acetone, insoluble in water, with a melting point of approximately 163°C and stable at room temperature. Ezetimibe only acts on the Chemicalbook small intestine, inhibiting the absorption of cholesterol and reducing the transport of intestinal cholesterol to the liver and reducing its storage; it can enhance the clearance of cholesterol in the blood, thereby reducing plasma cholesterol levels.
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
Ezetimibe, also known as ezetimibe and ezetimibe, is the first selective cholesterol absorption inhibitor jointly developed by Schering-Plough and Merck. This product is the first to be approved for marketing by the US FDA. Selective inhibitors of cholesterol absorption. Trade names are "EZETROL" and "EZETROL". Ezetimibe is a new type of selective cholesterol absorption inhibitor and the first selective inhibitor of intestinal cholesterol absorption. Its mechanism of action is similar to that of other lipid-lowering drugs (such as statins, bile acid sequestrants, Different from phenoxy acid derivatives and plant sterol esters), this product binds to the membrane proteins (relative molecular mass 145 Absorption of cholesterol in the tract, reducing cholesterol Chemicalbook levels in serum and liver. Unlike bile acid chelators, ezetimibe does not affect the absorption of cholesterol esters, other steroids (such as taurocholate), triacylglycerols, and fat-soluble vitamins. Its pharmacological effects have nothing to do with the inhibition of acetyl-CoA-cholesterol acetyltransferase (ACAT) and the expression of LDL receptor (scavenger receptor). After being absorbed, ezetimibe is conjugated with glucuronic acid in the liver and undergoes enterohepatic circulation, where it is almost specifically localized in small intestinal mucosal cells. This product can be used alone or in combination with HMG-CoA reductase inhibitors (statins) to treat primary (heterozygous familial or non-familial) hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH). , Homozygous sitosterolemia (or phytosterolemia). The above information was edited and compiled by Andy from Chemicalbook.
Items | Specifications |
---|---|
SOLUBILITY | Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 15 mg/ml) |
color | White or off-white |
Stable | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
Ezetimibe
2-Azetidinone,1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-,(3R,4S)-;2-Azetidinone,1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-,[3R-[3α(S*),4β]]-;(3R,4S)-1-(4-Fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone;Sch 58235;Ezetimibe;(-)-Sch 58235;Zetia;Ezetrol;Ezta;Ezedoc;1-(4-Fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)azetidin-2-one;Ezentia
163222-33-1
C24H21F2NO3
InChIKey=OLNTVTPDXPETLC-XPWALMASSA-N
409.43
409.43
1308068-626-2
EOR26LQQ24
DTXSID1044223
C47529
White solid
C10B|C10AX09|C - Cardiovascular system
29337900